Drug Profile
Research programme: mitoxantrone nanoparticles - Capsulution Pharma
Alternative Names: Mitoxanthrone nanoparticles - NanoDel; Mitoxantrone nanoparticles - NanoDelLatest Information Update: 06 Oct 2021
Price :
$50
*
At a glance
- Originator NanoDel Technologies
- Developer Capsulution Pharma
- Class Anthraquinones; Antineoplastics; Small molecules
- Mechanism of Action DNA intercalators; Type II DNA topoisomerase inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
Highest Development Phases
- No development reported Brain cancer
Most Recent Events
- 18 May 2011 No development reported - Preclinical for Brain cancer in Germany (unspecified route)
- 17 Aug 2005 Preclinical trials in Brain cancer in Germany (unspecified route)